Interleukin-35 expression protects against cigarette smoke-induced lung inflammation in mice
•IL-35 inhibits cigarette smoke-induced airway inflammation.•IL-35 reduces cigarette smoke-induced inflammatory cytokines production.•IL-35 increases anti-inflammatory cytokine IL-10 production in mice. Cigarette smoke (CS) is a very important cause of pulmonary inflammatory diseases. Interleukin (I...
Gespeichert in:
Veröffentlicht in: | Biomedicine & pharmacotherapy 2019-02, Vol.110, p.727-732 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •IL-35 inhibits cigarette smoke-induced airway inflammation.•IL-35 reduces cigarette smoke-induced inflammatory cytokines production.•IL-35 increases anti-inflammatory cytokine IL-10 production in mice.
Cigarette smoke (CS) is a very important cause of pulmonary inflammatory diseases. Interleukin (IL)-35 is a novel anti-inflammatory cytokine but its role in CS-mediated lung inflammation remains unclear. In the present study, we examined the effect of IL-35 expression on CS-induced lung inflammation in mice. A plasmid DNA expressing IL-35 was injected into mice via a hydrodynamic-based gene delivery that were subsequently exposed to CS three times a day for 5 days. We found that IL-35 expression inhibited pulmonary inflammatory infiltration, lung tissue lesions, mucus secretion, and myeloperoxidase activity in CS-treated mice. Moreover, IL-35 expression decreased the production of IL-1β, tumor necrosis factor-α, IL-6, and IL-17, but increased the level of IL-10 in bronchoalveolar lavage fluids and lung tissues from CS-challenged mice. These results suggest that in vivo expression of IL-35 can protect against CS-induced lung inflammation and may be a therapeutic target in CS-related pulmonary diseases. |
---|---|
ISSN: | 0753-3322 1950-6007 |
DOI: | 10.1016/j.biopha.2018.12.028 |